SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics

2025-03-13 11:16:52

(MENAFN- PR Newswire)

On February 7, 2025, Pliant issued a press release "announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF)." Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward.

On this news, Pliant's stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025.

To learn more about the Pliant Therapeutics investigation, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

MENAFN13032025003732001241ID1109311936

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.